Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 7/20 | 0.46 |
| ▸ | LPL | P06858 | 5/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.46 |
| ▸ | F11 | P03951 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3261628 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LTA4HLPLLIPGF11 | |
| SCHEMBL3261633 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LTA4HLPLLIPGF11 | |
| SCHEMBL18580223 | 0.92 | ALDH1A1 (0.57) | ALDH1A1LTA4HLPLLIPGF11 | |
| SCHEMBL18579804 | 0.92 | ALDH1A1 (0.49) | ALDH1A1LTA4HLPLLIPGF11 | |
| SCHEMBL18580578 | 0.89 | LPL (0.50) | LPLLIPGF11ESR2 | |
| SCHEMBL3263221 | 0.85 | LPL (0.47) | LTA4HLPLLIPGF11ESR2 | |
| SCHEMBL3264388 | 0.85 | LPL (0.47) | LTA4HLPLLIPGF11ESR2 | |
| SCHEMBL3263222 | 0.85 | LPL (0.47) | LTA4HLPLLIPGF11ESR2 | |
| SCHEMBL18580257 | 0.84 | LPL (0.46) | LTA4HLPLLIPGF11ESR2 | |
| SCHEMBL3260869 | 0.82 | LPL (0.49) | LTA4HLPLLIPGF11ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-01-14 | — | — | US | disclosed |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | disclosed |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-03-16 | — | — | US | disclosed |
| EP-3344613-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| US-20190119252-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2019-04-25 | — | — | US | disclosed |
| US-10125118-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2018-11-13 | — | — | US | disclosed |
| EP-3344613-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | Dong-A Socio Holdings Co., Ltd. (KR) | 2018-07-11 | — | — | EP | disclosed |
| US-20170355690-A9 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-12-14 | — | — | US | disclosed |
| US-20170066742-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO LTD (KR) | 2017-03-09 | — | — | US | disclosed |
| WO-2017039331-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-03-09 | — | — | WO | disclosed |
| WO-2010010184-A1 | [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355690-A9 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | ALDH1A1 3115/4885LTA4H 4113/4885LPL 3708/4885 |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | ALDH1A1 3115/4885LTA4H 4113/4885LPL 3708/4885 |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | ALDH1A1 3115/4885LTA4H 4113/4885LPL 3708/4885 |
| US-10125118-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | ALDH1A1 3115/4885LTA4H 4113/4885LPL 3708/4885 |
| US-20190119252-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | ALDH1A1 3115/4885LTA4H 4113/4885LPL 3708/4885 |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | ALDH1A1 3115/4885LTA4H 4113/4885LPL 3708/4885 |
| US-20170066742-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | ALDH1A1 3115/4885LTA4H 4113/4885LPL 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.